Are investors shorting iBio?

iBio saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 161,700 shares, an increase of 172.7% from the March 15th total of 59,300 shares. Based on an average daily volume of 3,680,000 shares, the short-interest ratio is presently 0.0 days. Currently, 1.9% of the company's shares are short sold. View iBio's Short Interest .

How were iBio's earnings last quarter?

iBio, Inc. (NYSEAMERICAN:IBIO) announced its quarterly earnings data on Friday, February, 9th. The company reported ($2.42) earnings per share (EPS) for the quarter.

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO) , Vaxart (VXRT) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Heat Biologics (HTBX) , Novavax (NVAX) , Dynavax Technologies (DVAX) , Co-Diagnostics (CODX) , Nokia Oyj (NOK) and Moderna (MRNA) .

How do I buy shares of iBio?

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEAMERICAN:IBIO

iBio (IBIO) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free IBIO Stock Alerts

$1.72

-0.05 (-2.82%)

(As of 04:37 PM ET)

Compare

Today's Range: $1.67
▼
$1.81
50-Day Range: N/A
52-Week Range: $1.02
▼
$27.80

Volume: 94,926 shs
Average Volume: 3.19 million shs
Market Capitalization: $5.99 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Short Interest

Get iBio alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About iBio

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

IBIO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IBIO Stock News Headlines

April 11, 2024 | americanbankingnews.com

Short Interest in iBio, Inc. (NYSEAMERICAN:IBIO) Increases By 172.7%

March 27, 2024 | msn.com

US Futures Trend Higher Wednesday Pre-Bell as Investors Eye Impending Economic, Inflation Data Readings

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 27, 2024 | markets.businessinsider.com

IBio In Partnership With AstralBio; Shares Up In Pre-market

See More Headlines

Receive IBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/09/2024
Today: 4/19/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NYSEAMERICAN:IBIO
CUSIP: N/A
CIK: N/A
Web: www.ibioinc.com
Phone: 302-355-0650
Fax: 302-356-1173
Employees: 26
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-65,010,000.00
Net Margins: N/A
Pretax Margin: -41,546.00%
Return on Equity: -150.59%
Return on Assets: -52.83%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 0.91
Quick Ratio: 0.91

Sales & Book Value

Annual Sales: $2.38 million
Price / Sales: 2.56
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $15.15 per share
Price / Book: 0.12

Miscellaneous

Outstanding Shares: 3,480,000
Free Float: 3,445,000
Market Cap: $6.09 million
Optionable: N/A
Beta: -3.77

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Martin B. Brenner D.V.M. (Age 53)
Ph.D., CEO & Chief Scientific Officer
Comp: $577.31k
Mr. Felipe Duran (Age 44)
Chief Financial Officer
Comp: $1.07M
Stephen Kilmer
Investor Relations Officer
Mr. Marc Banjak J.D.
General Counsel
Mr. Robert B. Kay (Age 84)
Interim Secretary & Interim Treasurer
Comp: $92.69k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

IBIO Stock Analysis - Frequently Asked Questions

Are investors shorting iBio?: iBio saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 161,700 shares, an increase of 172.7% from the March 15th total of 59,300 shares. Based on an average daily volume of 3,680,000 shares, the short-interest ratio is presently 0.0 days. Currently, 1.9% of the company's shares are short sold.
View iBio's Short Interest.
How were iBio's earnings last quarter?: iBio, Inc. (NYSEAMERICAN:IBIO) announced its quarterly earnings data on Friday, February, 9th. The company reported ($2.42) earnings per share (EPS) for the quarter.
What other stocks do shareholders of iBio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA).
How do I buy shares of iBio?: Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:IBIO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial